BioCentury
ARTICLE | Emerging Company Profile

OncoPep: Smoldering solution

OncoPep developing multi-peptide vaccine for smoldering multiple myeloma

March 5, 2012 8:00 AM UTC

OncoPep Inc. is developing a multi-peptide cancer vaccine for a largely asymptomatic precursor to multiple myeloma. Because these patients remain immunocompetent, they should respond to an immunotherapy, which the company believes could become the treatment of choice based on its anticipated safety profile.

In February, OncoPep announced an exclusive license to PVX-410 from Dana-Farber Cancer Institute. The preclinical candidate contains four immunogenic HLA-A2-specific peptides: two derived from X-box binding protein 1 (XBP1) and one each from cell-surface glycoprotein CS1 and syndecan 1 (SDC1; CD138)...